Orange Grove Bio
Latest round
- Seed
Last raised
- Feb 2021
Total raised
- $2M
Investors
- 7
About Orange Grove Bio
Founded in 2019 and based in Michigan, US, Orange Grove Bio LLC operates as a developer of neutrophil treatments for diseases with dysregulation of immune signaling. The company was founded by Marc Appel. In October 2021, IpiNovyx Bio, Inc. The company offers neutrophil targeting novel drug treatment for neutrophil-mediated diseases like Covid-19. The company also develops drugs in oncology, inflammatory, and autoimmune disease treatments, and different therapeutic modalities.
Who invested in Orange Grove Bio
7 investors across 1 round
See all investors in Orange Grove Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Feb 23, 2021
Amount
$2M
Investors
Questions about Orange Grove Bio
Who invested in Orange Grove Bio?
Orange Grove Bio has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Orange Grove Bio raised?
Orange Grove Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Orange Grove Bio last raise money?
Orange Grove Bio's most recent round on record is a Seed, in Feb 2021.
What does Orange Grove Bio do?
Founded in 2019 and based in Michigan, US, Orange Grove Bio LLC operates as a developer of neutrophil treatments for diseases with dysregulation of immune signaling.
Where is Orange Grove Bio headquartered?
Orange Grove Bio is headquartered in Cincinnati, US.
Which VCs invest in companies like Orange Grove Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Orange Grove Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Orange Grove Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.